Ullmann Claudio Dansky - 13 Feb 2025 Form 4 Insider Report for Context Therapeutics Inc. (CNTX)

Reporting relationship: Chief Medical Officer
Issuer ticker: CNTX
Reported as of: 13 Feb 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Feb 2025, 16:07:37 UTC
Prior SEC filing: 01 Aug 2024
Source filing: View source filing
Reporting owner signature: /s/ Alex Levit, Attorney-in-Fact

Key filing fact

Ullmann Claudio Dansky filed Form 4 for Context Therapeutics Inc. (CNTX) on 14 Feb 2025.

Key facts

This page summarizes Ullmann Claudio Dansky's Form 4 filing for Context Therapeutics Inc. (CNTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Feb 2025, 16:07.

Change

Previous filing in this sequence was filed on 01 Aug 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CNTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +174,960
Change %
Price: $0.000000
Shares after: 174,960
Date: 13 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 174,960
Exercise price: $0.8100
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 13, 2026, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.